Peter Sand to Muscarinic Antagonists
This is a "connection" page, showing publications Peter Sand has written about Muscarinic Antagonists.
Connection Strength
5.421
-
Oxybutynin: past, present, and future. Int Urogynecol J. 2013 Apr; 24(4):595-604.
Score: 0.423
-
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012 Feb 01; 29(2):119-31.
Score: 0.406
-
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb; 206(2):168.e1-6.
Score: 0.392
-
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
Score: 0.366
-
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010 Sep; 106(6):816-21.
Score: 0.354
-
The evolution of transdermal therapy for overactive bladder. Curr Urol Rep. 2009 Sep; 10(5):338-41.
Score: 0.343
-
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul; 20(7):827-35.
Score: 0.332
-
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jun; 20(6):667-75.
Score: 0.332
-
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
Score: 0.328
-
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int. 2007 Apr; 99(4):836-44.
Score: 0.284
-
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006 Dec; 195(6):1730-5.
Score: 0.283
-
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol. 2005 Jun; 192(6):1849-54; discussion 1854-5.
Score: 0.255
-
Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opin Pharmacother. 2004 Nov; 5(11):2351-9.
Score: 0.245
-
Elevating our therapeutic expectations in overactive bladder. J Am Acad Nurse Pract. 2004 Oct; 16(10 Suppl):8-11.
Score: 0.244
-
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
Score: 0.096
-
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig. 2011; 31(8):559-571.
Score: 0.094
-
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
Score: 0.087
-
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr; 181(4):1764-72.
Score: 0.083
-
Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn. 2008; 27(1):34-9.
Score: 0.076
-
Evaluation and treatment of female urinary incontinence. Minerva Urol Nefrol. 2007 Dec; 59(4):431-50.
Score: 0.076
-
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
Score: 0.075
-
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
Score: 0.072
-
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006 Nov; 28(11):1935-46.
Score: 0.070
-
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun; 78(6):687-95.
Score: 0.056
-
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
Score: 0.048